Secondhand Tobacco Smoke and Cardiovascular Disease
Sponsor: University of California, San Francisco • ClinicalTrials.gov ID: NCT04715568
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Interventions
-
Losartan
(Drug)
50 mg tablets taken orally
-
Placebo
(Drug)
Tablets taken orally
Eligibility criteria
Conditions
Locations
- San Francisco Veterans' Affairs Medical Center — San Francisco, California, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record